Which Side Will Makary Take In The Fight Over Weight Loss Drugs? [Forbes]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Forbes
Health, Education, Labor and Pensions Committee for his confirmation hearing on Thursday, March 6, 2025. (Bill Clark/CQ-Roll Call, Inc via Getty Images) CQ-Roll Call, Inc via Getty Images Last evening, Dr. Marty Makary, President Trump's pick to lead the U.S. Food and Drug Administration (FDA) was confirmed by the Senate by a vote of 56 to 44. One of the first and most consequential challenges he'll face is determining how the FDA will resolve a battle that pits Novo Nordisk and Eli Lilly, two multinational drug companies that manufacture hugely popular (and equally expensive) weight loss drugs against hundreds of FDA or state-licensed that produce lower-cost versions that contain the same active pharmaceutical ingredients. Which side Makary takes in this fight could affect tens of billions of dollars in health care spending and the health of millions of Americans. How We Reached This Point Glucagon-like peptide-1 (GLP-1) receptor agonists grew out of National Institutes of He
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 [Yahoo! Finance]Yahoo! Finance
- 2 Predictions for Novo Nordisk in 2026 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: The Right Long-Term Strategy [Seeking Alpha]Seeking Alpha
- Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss [Yahoo! Finance]Yahoo! Finance
- SA analyst upgrades/downgrades: NVO, INTC, ADBE, WDAY [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website